Company news
Zhejiang Orient Gene Biotech Co., Ltd. Class A (SSE:688298) news
Zhejiang Orient Gene Biotech Co., Ltd. Class A news releases on 6ix. Latest, Sep 12, 2026: "Zhejiang Orient Gene Biotech Co., Ltd."Announcement on Voluntary…
Press releases & updates
"Zhejiang Orient Gene Biotech Co., Ltd."Announcement on Voluntary Disclosure of Obtaining a Medical Device Registration Certificate
September 11, 2026
"Zhejiang Orient Gene Biotech Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Medical Device Registration Certificate
September 3, 2026
"Zhejiang Orient Gene Biotech Co., Ltd."Semi-annual Report for 2026
August 28, 2026
Announcement on SSE’s Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
June 12, 2026
Announcement on Voluntary Disclosure of Obtaining Medical Device Registration Certificate
May 26, 2026
Announcement on Election of Employee Representative Directors for the 4th Board of Directors
May 20, 2026
Announcement on Carrying out Forward Foreign Exchange Trading Business in 2026
April 28, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
February 26, 2026
Announcement on Resolutions of the 17th Meeting of the 3rd Board of Directors
February 9, 2026
Announcement on Expected Loss in Performance for 2025
January 29, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
January 13, 2026
Announcement on Resolutions of the 16th Meeting of the 3rd Board of Directors
December 26, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
November 20, 2025
Announcement on Election of Independent Directors and Adjustment of Special Committees and Their Members
November 4, 2025
Report for Q3 2025
October 30, 2025
Announcement on Dismissal of Employee Representative Supervisor and Election of Employee Representative Director
September 15, 2025
Announcement on Implementation Result of Shares Repurchase and Share Changes
September 11, 2025
Announcement on Resignation of Independent Director
September 9, 2025
Announcement on Progress in Repurchasing Shares through Call Auction
September 1, 2025
Announcement on Resolutions of the 14th Meeting of the 3rd Board of Directors
August 28, 2025
Neopharma Technologies and Orient Gene Partner to Digitize Healgen® Drug Test Portfolio Globally with NEOVAULT®
August 25, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
July 25, 2025
Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders Without Sales Limit Concerning Shares Repurchase
July 4, 2025
Announcement on Resolutions of the 13th Meeting of the 3rd Board of Directors
June 27, 2025
Indicative Announcement on Proposal of Chairman to Repurchase Shares
June 17, 2025
Announcement on Resolutions of the 2024 Annual General Meeting
May 28, 2025
Announcement on Voluntary Disclosure of Obtaining Medical Device Registration Certificate and CNAS (China National Accreditation Service for Conformity Assessment) Laboratory Accreditation Certificate
May 20, 2025
Report for Q1 2025
April 29, 2025
Announcement on Relevant Matters
March 28, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025